Scioderm Obtains $20,000,000 Series B Funding Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=41f59981-9b47-4be8-938f-dc3247e75391
Date
12/19/2014
Company Name
Scioderm
Mailing Address
1007 Slater Road Durham, NC 27703 USA
Company Description
The core business focus of Scioderm is the development of innovative dermatological drugs. Our strategy is to in-license or acquire early to mid-stage pharmaceutical products with the intent to develop the topical products.
Website
http://www.sderm.com
Transaction Type
Venture Equity
Transaction Amount
$20,000,000
Transaction Round
Series B
Proceeds Purposes
The proceeds will be used to fund the development of ZorblisaTM (SD-101), a proprietary topical therapy being developed for the treatment of all patients with Epidermolysis Bullosa (EB), through completion of the US and EU clinical registration programs.
M&A Terms
Venture Investor
Venture Investor
Venture Investor